<DOC>
	<DOCNO>NCT00315445</DOCNO>
	<brief_summary>The objective study assess safety buprenorphine transdermal system ( 5 , 10 , 20 ) comparison placebo transdermal system immediate release oxycodone/ acetaminophen subject chronic back pain . The double-blind treatment intervention duration 84 day time supplemental analgesic medication ( non-steroidal anti-inflammatory drug ) allow subject addition study drug .</brief_summary>
	<brief_title>The Safety Efficacy Buprenorphine Transdermal System ( BTDS ) Subjects With Chronic Back Pain .</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic twenty-five year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Acetaminophen , hydrocodone drug combination</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>clinical evidence stable , chronic ( &gt; 2 month ) back pain related intervertebral disc disease , nerve root entrapment , spondylolithesis , osteoarthritis , similar nonmalignant condition . unacceptable pain control despite currently take nonsteroidal antiinflammatory drug consider therapeutic and/or tolerate dose , subject currently take &lt; /=2 shortacting opioid dos per day , subject take 312 shortacting opioid dos per day . receive opioids average daily dose &gt; 90 mg oral morphine equivalent receive 12 tablet per day shortacting opioidcontaining product . schedule surgery ( include dental ) involve use preoperative postoperative analgesic anesthetic study period . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>chronic back pain</keyword>
	<keyword>opioid</keyword>
	<keyword>transdermal</keyword>
</DOC>